Therapeutic Vaccines for Alzheimer’s — Are We Close Enough?
Published on 13 Dec, 2016
Download this report: Therapeutic Vaccines for Alzheimer’s — Are We Close Enough?
Dementia, a set of symptoms that include memory loss, difficulty while thinking, problem-solving, or trouble with language, causes a permanent decline in an afflicted person's ability to manage their own life.
Alzheimer's Disease (AD) is one of the most common causes of dementia, accounting for nearly 70% of documented cases across the world.
While researchers have made some headway over the years in their quest for a cure, current therapies simply target Alzheimer's symptoms. Successful cures for the underlying disease, or even the ability to delay its progression, still remain elusive.
The hunt is on for a breakthrough drug that could treat the underlying disease, arresting or delaying the cellular damage that causes Alzheimer's symptoms to worsen.
The development of AD vaccines has faced setbacks due to failures in a few late-phase clinical trials.
While some theories suggest that the failed clinical trials may be due low drug dosage administered during trial phases (as a safety precaution) others postulate that current treatments are targeting the wrong protein to begin with.
The pharmaceutical industry is exploring all available options to develop a successful therapy for AD.
The global market for Alzheimer’s treatment is expected to grow at a CAGR of 10.5% from $4.9 billion in 2013 to $13.3 billion by 2023.
Future research would lean toward the development of vaccines that possess new peptide candidates — such as tau proteins and protofibrils — as well as more accurate diagnosis with the aid of biomarkers. In addition, the advent of advanced therapies like CRISPR could make viable AD treatments well within reach.
This report covers current research into therapeutic vaccines for Alzheimer’s Disease (AD), with topics that include market drivers, challenges associated with developing safe next-gen therapeutics, vaccines and therapies currently under development, as well as the technology and commercial ecosystem for AD therapy.